Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets


Out-
      side
 



 
 'MS-325' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'MS-325' found in 1 term [] and 3 definitions []
1 - 4 (of 4)     
Result Pages : [1]
Searchterm 'MS-325' was also found in the following services: 
spacer
News  (2)  Forum  (1)  
 
MS-325Forum -
related threadsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
MS-325 is the formerly code name of gadofosveset trisodium (new trade name Vasovist). MS-325 belongs to a new class of blood pool agents for magnetic resonance angiography (MRA) to diagnose vascular disease. Gadofosveset trisodium has ten times the signal-enhancing power of existing contrast agents as well as prolonged retention in the blood. This enables the rapid acquisition of high resolution MRA´s using standard MRI machines.
Gadofosveset trisodium, which is gadolinium-based, stays in the blood stream as a result of transient binding to albumin. Albumin binding offers an additional benefit beyond localization in the blood pool. The contrast agent begins to spin much more slowly, at the rate albumin spins, causing a relaxivity gain that produces a substantially brighter signal than would be possible with freely circulating gadolinium. MS-325 is an intravascular contrast agent intended for use in MRI as an aid in diagnosing aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease (PVD) or abdominal aortic aneurysm (AAA).
Currently clinical trials completed for peripheral vascular disease and coronary artery disease. Additional trials are also being conducted to evaluate MS-325 as an aid in diagnosing breast cancer and suggested that it might be feasible to combine the use of MS-325, injected during peak stress, with delayed high-resolution imaging to identify myocardial perfusion defects.
Vasovist (MS-325) would compete with the contrast agents Ferumoxytol (Code 7228) from AMAG Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham, but their further development is uncertain.
Partners in development: EPIX Pharmaceuticals, Inc., Mallinckrodt Inc., and Bayer Schering Pharma AG. Bayer Schering Pharma has the worldwide marketing rights for the product.
Formerly known under the Mallinckrodt trademark name, AngioMARK®.
See also Classifications, Characteristics, etc.
spacer
 
• Share the entry 'MS-325':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'MS-325' (10).Open this link in a new window.
 
Further Reading:
  News & More:
EPIX Medical's new multimedia Web site features AngioMARK images in 3D
Friday, 5 March 1999
MRI technology combined with contrast agent optimizes diagnosis of cardiovascular disease
1999
MRI Resources 
Pathology - MR Guided Interventions - Spine MRI - Musculoskeletal and Joint MRI - Anatomy - Software
 
Vasovist™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Vasovist™ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovist™ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovist™ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVAR™), to Lantheus Medical Imaging, Inc..
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.
See also MRI Safety.

Drug Information and Specification
NAME OF COMPOUND Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
DEVELOPER EPIX Pharmaceuticals, Inc. Bayer Schering Pharma AG
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, predominantly positive enhancement
RELAXIVITY 20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC Intravascular, short elimination half life
OSMOLALITY 825 mOsmol/kg H2O
CONCENTRATION 244 mg/mL, 0.25mmol/mL
DOSAGE 0.12 mL/kg, 0.03 mmol/kg
PREPARATION ready to use
INDICATION Contrast enhanced magnetic resonance angiography
DEVELOPMENT STAGE approved
DISTRIBUTOR See below
PRESENTATION 10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Vasovist® ? ?
North America, Australia ABLAVAR™ for sale Lantheus Medical Imaging, Inc

spacer

• View the DATABASE results for 'Vasovist™' (7).Open this link in a new window

 
Further Reading:
  Basics:
EPIX Medical's new multimedia Web site features AngioMARK images in 3D
Friday, 5 March 1999
MRI technology combined with contrast agent optimizes diagnosis of cardiovascular disease
1999
MRI Resources 
Knee MRI - Pathology - Spectroscopy - Jobs - Quality Advice - MRI Reimbursement
 
ABLAVAR™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
ABLAVAR™ (formerly named Vasovist™) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVAR™ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.

Drug Information and Specification
NAME OF COMPOUND Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
DEVELOPER EPIX Pharmaceuticals, Inc.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, predominantly positive enhancement
RELAXIVITY 20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC Intravascular
OSMOLALITY 825 mOsmol/kg H2O
CONCENTRATION 244 mg/mL, 0.25mmol/mL
DOSAGE 0.12 mL/kg, 0.03 mmol/kg
PREPARATION ready to use
INDICATION Contrast enhanced magnetic resonance angiography
DEVELOPMENT STAGE FDA approved
DISTRIBUTOR See below
PRESENTATION 10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Vasovist® Approved ?
USA, Canada, Australia ABLAVAR™ Approved Lantheus Medical Imaging, Inc.

spacer

• View the DATABASE results for 'ABLAVAR™' (3).Open this link in a new window


• View the NEWS results for 'ABLAVAR™' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
Searchterm 'MS-325' was also found in the following services: 
spacer
News  (2)  Forum  (1)  
 
EPIX Pharmaceuticals, Inc.MRI Resource Directory:
 - Developers -
 
www.epixmed.com

[This entry is marked for removal.]

(July 20, 2009 - EPIX Pharmaceuticals, Inc. announced today that, in light of the company's lack of capital and inability to obtain additional financing or consummate a strategic transaction, it has entered into an Assignment for the Benefit of Creditors, effective immediately, in accordance with Massachusetts law).
EPIX has been a specialty pharmaceutical firm developing targeted contrast agents to improve the capability of MRI as a diagnostic tool for a variety of diseases. Gadofosveset trisodium (formerly MS-325, Vasovist™, now ABLAVARt™), is an injectable intravascular contrast agents designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX conducted a pivotal Phase III trial for the detection of peripheral vascular disease, as well as a Phase II feasibility trial for coronary artery disease diagnosis.
To ensure rapid development and adoption of gadofosveset trisodium into clinical practice upon regulatory approval, EPIX pursued an aggressive product development plan and commercialization strategy. The Company established an exclusive, worldwide sales and marketing agreement with Bayer Schering Pharma AG. EPIX also established corporate collaborations with GE Healthcare, Philips Medical Systems and Siemens Medical Systems, the three leading MRI manufacturers, which together account for approximately 80 percent of the MRI machines installed worldwide.
EPIX had other MRI contrast agents under development, most significantly a novel prototype blood clot agent (EP-2104R). Potential clinical applications for this type of agent include detection of deep venous thrombosis, pulmonary embolism and blood clots in the coronary and carotid arteries. Currently, there is no high resolution imaging technique to directly visualize blood clots in patients with suspected cardiovascular disease.

Contact Information
MAIL EPIX Pharmaceuticals, Inc.
71 Rogers Street
Cambridge, MA 02142-1118
USA
PHONE +1-617-250-6000
FAX +1-617-250-6031
E-MAIL info@epixpharma.com
ONLINE www.epixpharma.com


spacer

• View the DATABASE results for 'EPIX Pharmaceuticals, Inc.' (7).Open this link in a new window


• View the NEWS results for 'EPIX Pharmaceuticals, Inc.' (69).Open this link in a new window.
 
Further Reading:
  Basics:
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
MRI Resources 
Portals - Mobile MRI Rental - Most Wanted - MRI Reimbursement - Safety Products - Spine MRI
 
     1 - 4 (of 4)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



PET-MRI is :
a valuable new tool 
worth to develop more 
unnecessary 
too expensive 
only for research 
the replacement for PET-CT 
for vets only 

Look
      Ups





Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2014 SoftWays. All rights reserved. [ 24 November 2014]
Terms of Use | Privacy Policy | Advertising
 [last update: 2014-11-24 03:47:17]